Processa Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Processa Pharmaceuticals, Inc. (PCSA) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $196.32 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $196.32K.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $1.69M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $5.54M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $6.31M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations as first filed |
|---|---|---|
| 2026-06-30 | $196.32K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $1.69M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $5.54M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $6.31M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $6.94M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $2.90M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $1.19M 10-Q · filed 2026-08-14 | |
| 2024-09-30 | $2.89M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $5.57M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $8.92M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $4.71M 10-K · filed 2026-03-18 | |
| 2023-09-30 | $6.86M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $8.68M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $10.74M 10-Q · filed 2024-05-10 | |
| 2022-12-31 | $6.50M 10-K · filed 2025-03-20 | |
| 2022-09-30 | $9.05M 10-Q · filed 2023-11-13 | $9.05M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $12.06M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $14.39M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $16.50M 10-K · filed 2024-03-29 | |
| 2021-09-30 | $19.09M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $20.83M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $23.05M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $15.42M 10-K · filed 2023-03-30 | |
| 2020-09-30 | $325.43K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $452.65K 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $142.28K 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $691.54K 10-K · filed 2022-03-30 | |
| 2019-09-30 | $504.30K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $721.99K 10-Q · filed 2020-08-05 | |
| 2019-03-31 | $1.25M 10-Q · filed 2020-05-15 | |
| 2018-12-31 | $1.74M 10-K · filed 2021-03-25 | |
| 2018-09-30 | $2.42M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $2.85M 10-Q · filed 2019-08-14 | |
| 2017-12-31 | $2.85M 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |